Business
Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026
Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced that results from its Phase 1a trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, which is being held from May 29-June 2, 2026, in Chicago, IL. The abstract titled "A phase 1 study to evaluate safety, tolerability, and pharmacokinetics of LNP8701 (SOS1 inhibitor) in subjects with metastatic sol
About this update from Lupin Limited
[{"type":"text","content":"MUMBAI, India and NAPLES, Fla. and CHICAGO, May 28, 2026 /PRNewswire/ -- Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced that results from its Phase 1a trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, which is being held from May 29-June 2, 2026, in Chicago, IL. The abstract titled "A phase 1 study to evaluate safety, tolerability, and pharmacokinetics of LNP8701 (SOS1 inhibitor) in subjects with metastatic solid tumors" has been published in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology track and can be viewed on the ASCO website (https://www.asco.org/abstracts-presentations/264586).","length":791,"tagName":"p"},{"type":"image","alt":"Lupin Logo (PRNewsfoto/Lupin Limited)","displaySize":"","headline":null,"caption":"Lupin Logo (PRNewsfoto/Lupin Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":331,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/0d2424ae8b9a41b9324c931bddd820bb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DwAsAo7_bk95ztCXEsgP0A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTc3Mw--/https://media.zenfs.com/en/prnewswire.com/0d2424ae8b9a41b9324c931bddd820bb","width":331,"height":400},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/DwAsAo7_bk95ztCXEsgP0A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTc3Mw--/https://media.zenfs.com/en/prnewswire.com/0d2424ae8b9a41b9324c931bddd820bb","width":331,"height":400}},"href":"https://mma.prnewswire.com/media/2461104/Lupin_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The abstract reports the findings from an ongoing first-in-human study of LNP8701 in patients with solid tumors. LNP8701 is an orally administered, investigational SOS1 (Son of Sevenless1) inhibitor, designed to block SOS1-mediated RAS activation, thereby limiting oncogenic signaling that promotes tumor growth. Results indicate that LNP8701 was well tolerated with desirable safety, pharmacokinetics profile and favorable anti-tumor activity. The preliminary efficacy findings demonstrate that two patients completed LNP8701 monotherapy for 12 cycles (i.e., 1 year) and one patient completed 14 cycles with stable disease.","length":624,"tagName":"p"},{"typ...